Syneos joins with physIQ, InCarda on atrial fibrillation study
The physIQ monitoring platform will be used to evaluate an inhaled treatment, developed by InCarda, that is intended to treat atrial fibrillation patients.
The physIQ monitoring platform will be used to evaluate an inhaled treatment, developed by InCarda, that is intended to treat atrial fibrillation patients.
A representative from the R&D tech provider offers advice on how to wrangle with a stressful, complicated process for better results and fewer headaches.
Organization extends turnkey research facility network to San Diego, San Francisco, Thousand Oaks, and Seattle.